Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITRM NYSE:MTNB NASDAQ:PYRGF NASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITRMIterum Therapeutics$0.68-0.7%$0.79$0.61▼$3.02$32.04M3.04605,621 shs240,870 shsMTNBMatinas Biopharma$1.70-2.9%$1.40$0.47▼$4.25$8.65M1.41413,845 shs48,801 shsPYRGFPyroGenesis Canada$0.19+2.7%$0.26$0.17▼$0.71$36.19M0.8114,554 shs9,060 shsRENBRenovaro$0.18-4.0%$0.26$0.17▼$2.10$31.50M0.542.04 million shs2.78 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITRMIterum Therapeutics+0.22%+3.59%-20.75%-30.20%-37.25%MTNBMatinas Biopharma-4.37%+4.79%-25.85%+91.47%+842.38%PYRGFPyroGenesis Canada-2.64%+0.37%-27.20%-45.73%-68.71%RENBRenovaro-4.03%+1.38%-20.24%-46.95%-70.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITRMIterum Therapeutics$0.68-0.7%$0.79$0.61▼$3.02$32.04M3.04605,621 shs240,870 shsMTNBMatinas Biopharma$1.70-2.9%$1.40$0.47▼$4.25$8.65M1.41413,845 shs48,801 shsPYRGFPyroGenesis Canada$0.19+2.7%$0.26$0.17▼$0.71$36.19M0.8114,554 shs9,060 shsRENBRenovaro$0.18-4.0%$0.26$0.17▼$2.10$31.50M0.542.04 million shs2.78 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITRMIterum Therapeutics+0.22%+3.59%-20.75%-30.20%-37.25%MTNBMatinas Biopharma-4.37%+4.79%-25.85%+91.47%+842.38%PYRGFPyroGenesis Canada-2.64%+0.37%-27.20%-45.73%-68.71%RENBRenovaro-4.03%+1.38%-20.24%-46.95%-70.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITRMIterum Therapeutics 3.00Buy$9.001,224.89% UpsideMTNBMatinas Biopharma 2.00HoldN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ARENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AMTNBMatinas BiopharmaN/AN/AN/AN/A$4.43 per shareN/APYRGFPyroGenesis Canada$9.14M3.96N/AN/A($0.01) per share-19.30RENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)MTNBMatinas Biopharma-$22.94M-$3.89N/A∞N/AN/A-123.06%-94.28%N/APYRGFPyroGenesis Canada-$21.12M-$0.03N/A∞N/A-115.14%N/A-60.81%N/ARENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%9/29/2025 (Estimated)Latest MTNB, RENB, PYRGF, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITRMIterum TherapeuticsN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITRMIterum TherapeuticsN/A2.692.52MTNBMatinas BiopharmaN/A5.535.53PYRGFPyroGenesis CanadaN/A0.600.50RENBRenovaroN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITRMIterum Therapeutics9.21%MTNBMatinas Biopharma11.77%PYRGFPyroGenesis Canada0.03%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipITRMIterum Therapeutics2.40%MTNBMatinas Biopharma4.60%PYRGFPyroGenesis Canada47.68%RENBRenovaro0.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITRMIterum Therapeutics1047.17 million46.04 millionNot OptionableMTNBMatinas Biopharma305.09 million4.60 millionN/APYRGFPyroGenesis Canada90187.53 million96.34 millionNo DataRENBRenovaro20172.12 million171.26 millionOptionableMTNB, RENB, PYRGF, and ITRM HeadlinesRecent News About These CompaniesLunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder TherapeuticsSeptember 11, 2025 | accessnewswire.comARenovaro Inc.: Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven InitiativesSeptember 9, 2025 | finanznachrichten.deLunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug DiscoverySeptember 9, 2025 | accessnewswire.comALunai Bioworks Strengthens European Strategy Through RestructuringSeptember 8, 2025 | accessnewswire.comARenovaro BioSciences retains American Defense InternationalSeptember 4, 2025 | msn.comLunai Bioworks Inc. Retains American Defense InternationalSeptember 4, 2025 | accessnewswire.comARenovaro BioSciences to change corporate name to ‘Lunai Bioworks’August 28, 2025 | msn.comRenovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced DiagnosticsAugust 27, 2025 | accessnewswire.comARenovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense RisksAugust 8, 2025 | accessnewswire.comARenovaro Biosciences Granted Nasdaq Compliance ExtensionAugust 6, 2025 | tipranks.comAI Just Got a Green Light from the White House--Here's What That Means for Healthcare StocksJuly 30, 2025 | tmcnet.comRenovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI SectorJuly 28, 2025 | accessnewswire.comARenovaro Biosciences: Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyJuly 17, 2025 | finanznachrichten.dePeer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyJuly 17, 2025 | accessnewswire.comARenovaro Biosciences Receives Nasdaq Compliance NoticeJuly 14, 2025 | tipranks.comRenovaro Strengthens Balance Sheet Through Debt ... - MorningstarJuly 11, 2025 | morningstar.comMRenovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven InitiativesJuly 9, 2025 | accessnewswire.comARenovaro Biosciences Restructures Debt with Exchange AgreementJuly 9, 2025 | tipranks.comRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - NasdaqJuly 2, 2025 | nasdaq.comRenovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTNB, RENB, PYRGF, and ITRM Company DescriptionsIterum Therapeutics NASDAQ:ITRM$0.68 0.00 (-0.69%) Closing price 04:00 PM EasternExtended Trading$0.69 +0.01 (+1.58%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Matinas Biopharma NYSE:MTNB$1.70 -0.05 (-2.86%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.03 (+1.47%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.PyroGenesis Canada NASDAQ:PYRGF$0.19 +0.01 (+2.71%) As of 03:41 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Renovaro NASDAQ:RENB$0.18 -0.01 (-4.04%) Closing price 04:00 PM EasternExtended Trading$0.18 0.00 (-0.55%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
